Contralateral Axillary Lymph Node Metastases from Breast Carcinoma: Is it Time to Review TNM Cancer Staging?

Area of Science:

• Oncology
• Surgical Oncology
• Clinical Research

Background:

• Contralateral axillary lymph node metastasis (CAM) is an infrequent clinical condition.
• CAM is currently classified as M1, stage IV, disease, presenting a management challenge due to limited data.
• Its significance and therapeutic approach (curative vs. palliative) remain uncertain.

Purpose of the Study:

• To evaluate the clinical significance and outcomes of patients with metachronous CAM.
• To investigate the potential for reclassifying CAM within the TNM staging system.
• To assess the impact of curative-intent treatments on CAM patient survival.

Main Methods:

• Retrospective evaluation of 47 patients with pathologically confirmed metachronous CAM.
• Exclusion of patients with distant metastases at the time of CAM diagnosis.
• Analysis of outcomes including disease-free survival (DFS) and overall survival (OS) following surgery, systemic therapy, and radiotherapy (RT).

Main Results:

• Metachronous CAM occurred a median of 73 months after primary tumor diagnosis.
• At a median follow-up of 5.4 years, overall survival (OS) was 72% at 5 years and 61% at 8 years.
• Disease-free survival (DFS) was 61% at 5 years and 42% at 8 years.

Conclusions:

• CAM outcomes, particularly OS, appear better than other distant metastases when treated with curative intent.
• CAM may warrant reclassification from stage IV to N3 disease in the TNM system.
• This suggests a new clinical perspective for managing CAM, emphasizing curative treatment strategies.